Estelle Bourbon

Estelle Bourbon

Auto-generated profile, based on publicly available information

Estelle Bourbon

Department of Hematology, Hospices Civils de Lyon, Hopital Lyon-Sud, Claude Bernard Lyon 1 University, Lyon, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Blood
Verified
Journal Article
Closed access
PDF file
EBEstelle Bourbon
Estelle Bourbon
MHMaël Heiblig
Maël Heiblig
MVMathieu Gerfaud Valentin
Mathieu Gerfaud Valentin
TBThomas Barba
Thomas Barba
CDCécile-Audrey Durel
Cécile-Audrey Durel
PSPierre Sujobert
Pierre Sujobert
Bourbon et al describe a series of 19 patients from France with VEXAS syndrome, including a novel genetic aberration in UBA1, and the outcomes of treatment for those with and those without myelodysplasia.

1 October 2021 in Seminars in Hematology
Verified
Journal Article
Closed access
MHMaël Heiblig
Maël Heiblig
BPBhavisha A. Patel
Bhavisha A. Patel
EGEmma M. Groarke
Emma M. Groarke
EBEstelle Bourbon
Estelle Bourbon
PSPierre Sujobert
Pierre Sujobert

1 October 2021 in Bulletin du Cancer
Verified
Journal Article
Closed access
EBEstelle Bourbon
Estelle Bourbon
HGHervé Ghesquières
Hervé Ghesquières
EBEmmanuel Bachy
Emmanuel Bachy

26 June 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EBEstelle Bourbon
Estelle Bourbon
VAVincent Alcazer
Vincent Alcazer
ECEstelle Cheli
Estelle Cheli
SHSarah Huet
Sarah Huet
PSPierre Sujobert
Pierre Sujobert
The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor the response to treatment, and detect relapses earlier. One of the main challenges of the coming years is to adapt techniques from highly specialized translational teams to routine laboratories as this requires a careful technical and clinical validation, and we have to achieve this as fast as possible to transform a promising biomarker into a routine analysis to have a direct consequence on patient care. Whatever the analytical technology used, the prerequisite is to obtain high yields of ctDNA of optimal quality. In this review, we propose a step-by-step description of the preanalytical process to obtain high-quality ctDNA, emphasizing the technical choices that need to be made and the experimental data that can support these choices.

3 December 2025 in European Journal of Cancer
Verified
Journal Article
Open access
PSPierre Sesques
Pierre Sesques
GMGuillaume Manson
Guillaume Manson
SDSydney Dubois
Sydney Dubois
FGFrancois Xavier Gros
Francois Xavier Gros
GBGabriel Brisou
Gabriel Brisou
BTBenoit Tessoulin
Benoit Tessoulin
The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances in the understanding of LBCL biology, coupled with improvements in diagnostic and monitoring tools and therapeutic approaches, have significantly enhanced patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the LYSA (Lymphoma Study Association) for the management of LBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. They aim to provide clinicians with a clear, practical framework to optimize care for patients with LBCL, ensuring that the best available evidence is translated into clinical practice.

9 February 2023 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
EBEstelle Bourbon
Estelle Bourbon
KCKaddour Chabane
Kaddour Chabane
IMIsabelle Mosnier
Isabelle Mosnier
ABAnne Bouvard
Anne Bouvard
FTFlorian Thonier
Florian Thonier
SHSarah Huet
Sarah Huet